Pds biotechnology reports inducement grants under nasdaq listing rule 5635(c)(4)

Florham park, n.j., june 30, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech”), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced, on june 28, 2023, pds biotech granted nonstatutory stock options to purchase a total of 29,900 shares of common stock to four employees as a material inducement to employment with pds biotech and in accordance with nasdaq listing rule 5635(c)(4) and pds biotech's 2019 inducement plan, as amended, which was adopted on june 17, 2019 and provides for the granting of equity awards to new employees of pds biotech.
PDSB Ratings Summary
PDSB Quant Ranking